Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle
Authors:
Open Access
- 22 February 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep41904
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been known as a promising agent for cancer therapy due to its specific apoptosis-inducing effect on tumor cells rather than most normal cells. However, systemically delivered TRAIL suffers from a rapid clearance from the body with an extremely short half-life. Thermally responsive elastin-like polypeptides (ELPs) are a promising class of temperature sensitive biopolymers based on the structural motif found in mammalian tropoelastin and retain the advantages of polymeric drug delivery systems. We therefore expressed RGD-TRAIL fused with ELP (RGD-TRAIL-ELP) inE. coli. Purification of RGD-TRAIL-ELP was achieved by the conveniently inverse transition cycling (ITC). The purified RGD-TRAIL-ELP without any chemical conjugation was able to self-assemble into nanoparticle under physiological condition. Non-reducing SDS-PAGE results showed that trimer content of RGD-TRAIL-ELP increased 3.4-fold than RGD-TRAIL. Flow cytometry confirmed that RGD-TRAIL-ELP 3-fold enhanced apoptosis-inducing capacity than RGD-TRAIL. Single intraperitoneal injection of the RGD-TRAIL-ELP nanoparticle induced nearly complete tumor regression in the COLO-205 tumor xenograft model. Histological observation confirmed that RGD-TRAIL-ELP induced significant tumor cell apoptosis without apparent liver toxicity. These findings suggested that a great potential application of the RGD-TRAIL-ELP nanoparticle system as a safe and efficient delivery strategy for cancer therapy.Keywords
This publication has 50 references indexed in Scilit:
- TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancerJournal of Controlled Release, 2016
- Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesionsBiomaterials, 2014
- PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targetingJournal of Controlled Release, 2012
- Amphiphilic protein micelles for targeted in vivo imagingActa Biomaterialia, 2012
- Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticlesBiomaterials, 2011
- Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomesBiomaterials, 2010
- Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic ActivityCancer Research, 2004
- Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivoInternational Journal of Cancer, 2003
- Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy ReceptorsScience, 1997
- The Receptor for the Cytotoxic Ligand TRAILScience, 1997